Synonyms: Compound 7 [WO2021113627A1] | Journavx® | VX-548 | VX548
suzetrigine is an approved drug
Compound class:
Synthetic organic
Comment: Suzetrigine (VX-548) is an oral, selective NaV1.8 (SCN10A) allosteric inhibitor [2], that was developed for analgesic potential in acute and chronic pain [3]. NaV1.8 is validated target for peripheral pain management, that offers a non-opioid therapeutic option that mitigates the off-target effects of opioids in the brain. This chemical structure is claimed in Vertex Pharmaceuticals' patent WO2021113627A1 [1]. The ligand docks within the channel's second voltage sensing domain (VSD2) and stabilises its closed state [3]. Suzetrigine's FDA approval in early 2025 made it the first-in-class NaV1.8-targeting analgesic to reach the clinic.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|